The members of the National Executive Council (NEC) of Ghana National Chamber of Pharmacy (GNCoP) led by the Chairman Pharm. Harrison Abutiate, yesterday 16th February 2022 visited the Pharmaceutical Enclave located at the Dawa Industrial Zone.
The objective of the meeting was to apprise them on the progress of work that is ongoing at the Enclave. Members were impressed with the state of the ongoing drainage systems, establishment of 132 MVA power substation, fast speed fiber optic communication system and the road network linking to and within the Enclave.
So far 15 Pharma Companies at their various preparatory stages have expressed interest in setting up at the enclave, which translates to an estimated investment of over $150m with more than 3,600 full time direct employment to be created.
Dawa Industrial Zone is an initiative of LMI Holdings (a conglomerate with over $450 million worth of assets as a sole developer of the largest industrial park in Ghana). The project will attract investment in manufacturing medicines, packaging, and establishment of Laboratory services.
The Vision of Ghana National Chamber of Pharmacy is to make the pharma Enclave a preferred hub for Pharmaceutical, Chemical, manufacturing and services with world-class infrastructure and environment management. Ghana National Chamber of Pharmacy (GNCoP) shall endeavor to provide cutting edge community, pharmaceutical infrastructure to make members globally competitive and focus on their core competence.
Ghana National Chamber of Pharmacy (GNCoP) is facilitating the establishment of a Special Purpose Vehicle (SPV) for water treatment, Laboratory services, warehouse & logistics management, and utilities for the Enclave
Meanwhile with the support of Foreign, Commonwealth & Development Office (FCDO), Ghana, a consultant was engaged, and a report has been submitted on the investment opportunities and Legal structure of the Special Purpose Vehicle for the proposed pharmaceutical Enclave.
Ghana Pharma Market size in 2020 was $616 million expected to increase to $683.03 million by the end of 2022 with a growth rate of 5.3% per annum.
GNCoP urges the government to support with a pharma policy and an incentive package especially for those companies setting up at the DAWA enclave that will ensure access to essential medicines for everybody, quality assurance for all drugs on the market, a functioning and efficient supply chain as well as rational use of medicines by professionals and patients.
Contact Investor Relations:
Tel: 055 203 0000 / 055 204 0000